Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors.

<h4>Background</h4>Hepatocellular carcinoma (HCC) is characterized by late detection and fast progression, and it is believed that epigenetic disruption may be the cause of its molecular and clinicopathological heterogeneity. A better understanding of the global deregulation of methylati...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hector Hernandez-Vargas, Marie-Pierre Lambert, Florence Le Calvez-Kelm, Géraldine Gouysse, Sandrine McKay-Chopin, Sean V Tavtigian, Jean-Yves Scoazec, Zdenko Herceg
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2010
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/389baa5725c54169a07b5d9e17960c62
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:389baa5725c54169a07b5d9e17960c62
record_format	dspace
spelling	oai:doaj.org-article:389baa5725c54169a07b5d9e17960c622021-11-25T06:25:22ZHepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors.1932-620310.1371/journal.pone.0009749https://doaj.org/article/389baa5725c54169a07b5d9e17960c622010-03-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20305825/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Hepatocellular carcinoma (HCC) is characterized by late detection and fast progression, and it is believed that epigenetic disruption may be the cause of its molecular and clinicopathological heterogeneity. A better understanding of the global deregulation of methylation states and how they correlate with disease progression will aid in the design of strategies for earlier detection and better therapeutic decisions.<h4>Methods and findings</h4>We characterized the changes in promoter methylation in a series of 30 HCC tumors and their respective surrounding tissue and identified methylation signatures associated with major risk factors and clinical correlates. A wide panel of cancer-related gene promoters was analyzed using Illumina bead array technology, and CpG sites were then selected according to their ability to classify clinicopathological parameters. An independent series of HCC tumors and matched surrounding tissue was used for validation of the signatures. We were able to develop and validate a signature of methylation in HCC. This signature distinguished HCC from surrounding tissue and from other tumor types, and was independent of risk factors. However, aberrant methylation of an independent subset of promoters was associated with tumor progression and etiological risk factors (HBV or HCV infection and alcohol consumption). Interestingly, distinct methylation of an independent panel of gene promoters was strongly correlated with survival after cancer therapy.<h4>Conclusion</h4>Our study shows that HCC tumors exhibit specific DNA methylation signatures associated with major risk factors and tumor progression stage, with potential clinical applications in diagnosis and prognosis.Hector Hernandez-VargasMarie-Pierre LambertFlorence Le Calvez-KelmGéraldine GouysseSandrine McKay-ChopinSean V TavtigianJean-Yves ScoazecZdenko HercegPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 5, Iss 3, p e9749 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Hector Hernandez-Vargas Marie-Pierre Lambert Florence Le Calvez-Kelm Géraldine Gouysse Sandrine McKay-Chopin Sean V Tavtigian Jean-Yves Scoazec Zdenko Herceg Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors.
description	<h4>Background</h4>Hepatocellular carcinoma (HCC) is characterized by late detection and fast progression, and it is believed that epigenetic disruption may be the cause of its molecular and clinicopathological heterogeneity. A better understanding of the global deregulation of methylation states and how they correlate with disease progression will aid in the design of strategies for earlier detection and better therapeutic decisions.<h4>Methods and findings</h4>We characterized the changes in promoter methylation in a series of 30 HCC tumors and their respective surrounding tissue and identified methylation signatures associated with major risk factors and clinical correlates. A wide panel of cancer-related gene promoters was analyzed using Illumina bead array technology, and CpG sites were then selected according to their ability to classify clinicopathological parameters. An independent series of HCC tumors and matched surrounding tissue was used for validation of the signatures. We were able to develop and validate a signature of methylation in HCC. This signature distinguished HCC from surrounding tissue and from other tumor types, and was independent of risk factors. However, aberrant methylation of an independent subset of promoters was associated with tumor progression and etiological risk factors (HBV or HCV infection and alcohol consumption). Interestingly, distinct methylation of an independent panel of gene promoters was strongly correlated with survival after cancer therapy.<h4>Conclusion</h4>Our study shows that HCC tumors exhibit specific DNA methylation signatures associated with major risk factors and tumor progression stage, with potential clinical applications in diagnosis and prognosis.
format	article
author	Hector Hernandez-Vargas Marie-Pierre Lambert Florence Le Calvez-Kelm Géraldine Gouysse Sandrine McKay-Chopin Sean V Tavtigian Jean-Yves Scoazec Zdenko Herceg
author_facet	Hector Hernandez-Vargas Marie-Pierre Lambert Florence Le Calvez-Kelm Géraldine Gouysse Sandrine McKay-Chopin Sean V Tavtigian Jean-Yves Scoazec Zdenko Herceg
author_sort	Hector Hernandez-Vargas
title	Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors.
title_short	Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors.
title_full	Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors.
title_fullStr	Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors.
title_full_unstemmed	Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors.
title_sort	hepatocellular carcinoma displays distinct dna methylation signatures with potential as clinical predictors.
publisher	Public Library of Science (PLoS)
publishDate	2010
url	https://doaj.org/article/389baa5725c54169a07b5d9e17960c62
work_keys_str_mv	AT hectorhernandezvargas hepatocellularcarcinomadisplaysdistinctdnamethylationsignatureswithpotentialasclinicalpredictors AT mariepierrelambert hepatocellularcarcinomadisplaysdistinctdnamethylationsignatureswithpotentialasclinicalpredictors AT florencelecalvezkelm hepatocellularcarcinomadisplaysdistinctdnamethylationsignatureswithpotentialasclinicalpredictors AT geraldinegouysse hepatocellularcarcinomadisplaysdistinctdnamethylationsignatureswithpotentialasclinicalpredictors AT sandrinemckaychopin hepatocellularcarcinomadisplaysdistinctdnamethylationsignatureswithpotentialasclinicalpredictors AT seanvtavtigian hepatocellularcarcinomadisplaysdistinctdnamethylationsignatureswithpotentialasclinicalpredictors AT jeanyvesscoazec hepatocellularcarcinomadisplaysdistinctdnamethylationsignatureswithpotentialasclinicalpredictors AT zdenkoherceg hepatocellularcarcinomadisplaysdistinctdnamethylationsignatureswithpotentialasclinicalpredictors
_version_	1718413736102854656

Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors.

Ejemplares similares